{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreif4dpwigs3667p4hnk5y6nikllkjzhcqzwkrgo2bqud3uystvdaai",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mnxz5hp4nl32"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreicbjng4rzyxdrpj5nw7md2hhgwoaqwdd52jahqncgrkjcdwz5t2py"
    },
    "mimeType": "image/jpeg",
    "size": 65183
  },
  "path": "/news/2026-06-weekly-survodutide-linked-body-weight.html",
  "publishedAt": "2026-06-10T19:40:04.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "For adults with obesity without diabetes, once-weekly survodutide, an investigational glucagon receptor-glucagon-like peptide-1 receptor dual agonist, is associated with greater reductions in body weight than placebo, according to a study published online June 7 in the New England Journal of Medicine to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans.",
  "title": "Once-weekly survodutide linked to drop in body weight in obesity"
}